anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention is directed to a method of applying drug-release coatings whereby a polymer can be dissolved in a first solvent (solvent A) to form a polymer system and a drug can be dissolved or suspended in a second solvent (solvent B) to form a drug system.  The coating or layer of coating so formed comprises a substantially uniform combination of the drug and polymer.  Solvent B can be the same as or different than solvent A.  The coating can be applied on a stent body by separately spraying or dipping the polymer system and the drug system onto the devices.  The coating can be accomplished by either applying the polymer and drug systems sequentially or simultaneously.  In certain embodiments, a drug can be suspended in solvent B.  In some cases, three or more systems can be utilized.  For instance, a third system containing pure solvent A or B can smooth the coating surface, if the solvent of the third spraying system is compatible with the polymer matrix.
Participants received high-dose (HD) IL2, 600,000 IU/kg/dose (Prometheus Laboratories Inc.) i.v. every 8 hours for 5 days (maximum of 14 doses) beginning on day 1 and again on day 15. One course generally consisted of 5 days of treatment, 9 days of rest, 5 more days of treatment, and 9 weeks of rest, followed by up to two additional courses of HD IL2 for patients who benefited and tolerated most of the planned IL2 doses. A treatment delay of up to 4 weeks was allowed for resolution of side effects between courses. Patients were eligible to receive a maximum of three courses of treatment.
Abdominal aortic aneurysm (AAA) is characterized by localized structural deterioration of the aortic wall, leading to progressive dilatation and rupture. Protease activated receptor 2 (PAR2) dependent signaling has been implicated in the pathophysiology of atherosclerosis through the regulation of smooth muscle cell function. However, its role in AAA remains unclear. This study investigates the function and potential mechanism of PAR2 in AAA progression. Angiotensin II (Ang II) and β-aminopropionitrile (BAPN) were administered to wild type (WT) mice to induce AAA. Increased PAR2 expression was observed in the aneurysmal tissues of these mice and in Ang II-treated vascular smooth muscle cells (VSMCs). We demonstrated that PAR2 deficiency markedly inhibited aorta dilatation and vascular remodeling in the AAA model relative to WT mice. Immunohistochemical staining showed significant upregulation of contractile markers and a reduction in synthetic markers in PAR2 knockout mice. Consistent with in vivo results, PAR2 knockdown diminished the effects of Ang II on VSMCs phenotypic switching, resulting in reduced proliferation and migration. Conversely, a PAR2 agonist (SLIGRL) induced the opposite effect, which was partially mitigated by pretreatment with an extracellular signal-regulated kinase (ERK) inhibitor (PD98059). This study suggests that PAR2 deficiency restrains aortic expansion and mitigates adverse vascular remodeling in AAA models, mediated in part by the ERK signaling pathway, indicating that PAR2 could be a potential therapeutic target for mitigating AAA development or progression.
The principles of Pilates exercises will be taught to the patients in the first session, and the evaluation will be made. The exercises, including basic training exercises in the first week, will be performed for 6 weeks, each session lasting 45 minutes, two days a week, each exercise for 8-12 repetitions. The Pilates exercises, consisting of gradually increasing strengthening will be applied under the supervision of a physiotherapist.
A modified sol-gel method to create metal-rich siliceous material, such as colloidal silica or aluminosilicate particles is disclosed. Initially, the metal salt of choice is added to a silicic acid solution or a silicic acid solution containing aluminum salt. The aluminum is added to vary the metal-support interaction as it forms Al—O—Si linkages within the silica matrix. Besides aluminum, other metals can be added that form M—O—Si (M=Ti, B, etc.) linkages, which do not become reduced when treated with a reducing agent. Once the metal, silicic acid and/or aluminum salt is generated, it is subjected to colloidal growth by addition to a basic heel. Upon colloidal synthesis, the metal salt containing colloidal particle is left as is to maximize colloidal stability or is reduced with hydrazine to produce the zero valence metal-containing colloidal particle. Keeping a particle colloidal before use may be an effective method of forming a catalyst material as it can be easily spray-dried or mixed with other materials for extruded catalyst particles.
AIS is the most common spinal deformity seen by primary care physicians, pediatricians, and spinal surgeons. The primary goal in the conservative treatment of scoliosis in adolescents is to prevent the progression of the curvature and secondary problems associated with spinal deformity and ultimately to eliminate the need for surgery. For this reason, scoliosis-specific corrective exercise therapy given by a physiotherapist is recommended for patients with AIS. However, while this treatment is effective to the gold standard on spine and posture, its effect on physical activity is not known exactly. The aim of this study is to examine the effect of physical activity counseling on physical activity level and posture, perception of deformity and quality of life in individuals with AIS who are given physical activity counseling in addition to scoliosis-specific corrective exercises. Individuals with AIS in both groups, in accordance with the Schroth classification, individually planned exercise program aimed at correcting and stabilizing the spine in three dimensions, in the form of 45-60 minutes sessions, 2 days a week for 8 weeks, a total of 16 sessions. Group 1 will be given physical activity counseling as well as scoliosis-specific corrective exercises. Physical activity counseling will be done face-to-face, and one-on-one interviews will be provided with each participant. Each meeting will last approximately 20-30 minutes and individuals will be encouraged to participate in more physical activity by providing alternative solutions on their physical activity habits, what they like to do or how they can access activities.
Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days). Participants will be instructed to take the trial product in the morning after an overnight fast and wait 30 minutes before taking any food, water or other oral medication in accordance with the approved dosing schedule for oral semaglutide.
Patients will be recruited at the outpatient's department of the Medical University of Vienna - Otorhinolaryngology department. Patient will be asked to participate in the study when inclusion and exclusion criteria are met. Mostly patients scheduled for a surgery improving conductive hearing loss or scheduled for implantation of an implantable bone conduction hearing aid will be included in the study.

Patients who do not use a hearing aid and who are not planning on using a hearing aid meeting the inclusion and exclusion criteria will also be asked to participate in the study. After inclusion in the study patients will be asked to fill out two questionnaires (quality of life and hearing specific questionnaire). They will then be fitted with an ADHEAR device and undergo unaided and aided soundfield audiometry. Randomization will be carried out (Randomization ratio 1.4:1) and patients in the intervention group will keep the device for the following 4 months with one visit after the first probation time of one month. At the one month mark patients in the control group will be asked to fill out the two questionnaires. Patients in the control group will be asked to return to the department and fill out the three questionnaires (SSQ-12 (Speech Spatial and Hearing Questionnaire), AQoL(Assessment of Quality of Life) and In-house questionnaire). Further audiologic assessment will be carried out. At this appointment patients will be able to talk about their experiences in the probation period und easily terminate the study in case of insufficient improvement, pain, skin irritations or other issues. At the four month mark patients in both groups will be asked to return for audiologic assessment and for filling out the questionnaires.
The study will be conducted in 2 parts, separately for IV and SC administration: dose escalation (Part 1) and dose expansion (Part 2). It will evaluate safety, tolerability, pharmacokinetics and preliminary antitumor activity of Teclistamab administered to adult participants with relapsed or refractory multiple myeloma. The overall safety of the study drug will be assessed by physical examinations, Eastern Cooperative Oncology Group performance status, laboratory tests, vital signs, electrocardiograms, adverse event monitoring, and concomitant medication usage. Disease evaluations will include peripheral blood and bone marrow assessments at screening (performed within 28 days) and to confirm stringent complete response (sCR), complete response (CR), or relapse from CR. The end of study (study completion) is defined as 2 years after the last participant in Part 3 has received his or her initial dose of teclistamab. Study record NCT04557098 is Phase 2 part of this study and study record NCT03145181 is Phase 1 part of this study.
PURPOSE: Plutonium and iron share a common metabolism in terms of their transportation and accumulation in the human body. This study examined their concentrations in livers with different states of health, and the effects of fatty degeneration and cirrhosis on their accumulation in the liver.
MATERIALS AND METHODS: We determined the concentrations of plutonium and iron in autopsy liver samples from 1976-1979. Using statistical analysis, we investigated the relationships between the different variables.
RESULTS AND CONCLUSIONS: The burdens of 239,240Pu and Fe correlated positively (Rs = 0.411) in the healthy livers, but not in the livers that had pathological findings. In contrast to the Fe content, the 239,240Pu content in the fatty degenerated or cirrhotic livers was significantly lower than that in normal livers. This difference may suggest that plutonium and iron do not accumulate or are not excreted in the same way in fatty degenerated and cirrhotic livers. The reaction mechanisms for the binding and excretion of plutonium, particularly in a fatty degenerated liver, are not yet fully known.
Hepatocellular carcinoma is a second deadliest cancer in the world with less than 20% of patients eligible for curative surgery at the time of diagnosis. Yttrium-90 (Y90) radioembolization is palliative treatment with promising result. However, one of the most important factors in the success of Y90 treatment is to ensure adequate dose of radioactive material is delivered to the tumor. The technetium-99 macroaggregated albumin (MAA) which is currently used for Y90 treatment planning and shunt study does not predict distribution of Y90 in the lungs, tumors, and liver. Therefore, accurate and personalized treatment planning cannot be performed using MAA. In this study, we are proposing using low-dose Y90 microspheres for the planning stage of the therapy to obtain an accurate estimation of distribution of Y90 therapy dose. This will in turn allow us to ensure adequate dose of Y90 is delivered to the tumor(s) while minimizing dose delivered to non-tumor liver and lungs in order to decrease the chance of treatment related toxicity to the liver and lungs.
This is a prospective, observational, non-interventional, non-randomized study involving the adult patients undergoing Whipple's procedure. Institutional ethics permission and written informed consent will be taken from the patient. The study duration will be for a period of 5 years, but the data of the first one year will be analysed and will presented as a thesis for MD (Anaesthesia). Administration of anaesthesia and reversal of neuromuscular blocking drugs will be carried as per the institutional routine practice and at the discretion of anaesthesiologist in charge. The study will include patients undergoing Whipple's procedure for pancreatic cancer, between age group of 18-75years, with ASA-PS I - III. Preoperative, intraoperative and outcome variables as defined according to the definitions established by the American college of surgeons National Surgeons Quality Improvement Program (NSQIP) will be recorded. A total of 11 preoperative, 14 intraoperative and 21 outcome variables will be collected (see Appendix). All the post operative outcome variables will be defined. Preoperative comorbid conditions will also be recorded. SAS will be calculated from three intraoperative variables (1) the estimated blood loss (EBL), (2) lowest heart rate (HR), and (3) lowest mean arterial pressure (MAP). For analysis, SAS will be classified as low (≤ 4 points), intermediate (5-6 points) and high (7-9 points). Complications including mortality will be assessed Upto 30 days postoperatively. The categorization of the complications as major and minor is consistent with NSQIP definition. Major complications include acute kidney injury, blood loss ≥ 2000ml, transfusion requiring ≥ 4 U packed blood cells within 72 hours of surgery, cardiac or respiratory arrest requiring cardiopulmonary resuscitation (CPR), coma for 24 hours or longer, deep venous thrombosis, septic shock, acute myocardial infarction, new onset arrhythmias, unplanned re-intubation, ventilator use for 48 hours or longer, pneumonia, pulmonary embolism, stroke, wound disruption, deep or organ space surgical site infection, sepsis, systemic inflammatory response syndrome, unplanned intensive care unit (ICU) admission, need for reoperation, anastomotic leak or fistula, vascular, ureteral or neural injuries, unplanned readmission \< 30 days of discharge, and death. The occurrence of major postoperative complications within 30 days of surgery represents primary outcome. Some of the patients do follow-up at day 30 to the OPD and those patients who don't follow-up at day 30 will be assessed and interviewed by telephone. If they are not able to follow-up on day 30, they will be contacted telephonically and interviewed for a period of 10-15 minutes, by a research nurse or a research doctor. Only mortality will be noted at day 30.
Participants in the Standard Group will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (\> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. Standard group will receive no guidance on energy intake distribution (standard lifestyle intervention).
The present invention relates to novel peptides derived from the autoantigen HC gp-39, said peptides comprising at least one of the amino acid sequences FGRSFTLAS (SEQ ID No. 1), FTLASSETG (SEQ ID No. 2), YDDQESVKS (SEQ ID No. 3) and FSKIASNTQ (SEQ ID No. 4). The peptides resemble MHC Class II restricted T-cell epitopes present on the autoantigen HC gp-39 in articular cartilage. HC gp-39 and said peptides can be used in antigen-specific treatment of articular cartilage destruction in autoimmune diseases to induce tolerance of the immune system. The autoantigen HC gp-39 and said peptides are also suitable to induce arthritis in non-human animals, preferably mice. The invention furthermore relates to pharmaceutical compositions comprising said autoantigen and/or said peptides, a diagnostic method for the detection of autoreactive T cells in a test sample and test kits to be used in said method.
PURPOSE:To easily obtain at a low cost the title material useful as an antiobese food material etc., mild in digestion and absorption, thus causing no dyspepsia by binding a glycerin fatty acid ester to a starch to effect specifying the amylose occupancy rate in the starch by said fatty acid ester. CONSTITUTION:(A) 2-20 pts.wt. of a glycerin fatty acid ester (pref. an ester compound from glycerin and a 8-22C fatty acid such as caprylic acid; e.g. glyceryl monolaurate) is brought into contact with (B) 100 pts.wt. of a starch prepared from rice, wheat, corn etc., in the presence of (C) 5-500 pts.wt. of water, thus giving the objective material >=10% (pref. 40-95%) in the amylose occupancy rate in the starch by said glycerin fatty acid ester.
FIELD: medicine. SUBSTANCE: method involves manufacturing an intermediate product from double-layer material having internal layer interacting with injured skin area. The layer is impregnated with 100% natural propolis carried by bees. To achieve it, the intermediate product is placed into beehive during the period of bee activeness 0.5-1 cm far from honeycomb frame so that the internal layer of the intermediate product is turned towards the frame. The intermediate product is left there for 2-4 weeks. External layer material is selected as flexible material usable for fixing. Shape and size of the intermediate product is selected to match the injured skin area in shape and size. The intermediate product is manufactured as belt, brace, shoulder piece, knee piece, elbow piece, pulse zone piece, talocrural piece, finger piece, sock or bandage. EFFECT: simplified production; enhanced effectiveness of treatment. 4 cl
FIELD: medicine, particularly, methods of treating deep mycoses. SUBSTANCE: this method prescribes carrying out comprehensive treatment, that is, intramuscularly administering 3 ml of actinolysate two times a week, 1 g of sulfanilamide four times a week during 3 to 4 weeks, vitamins of groups B and C, carrying out hemotransfusion and transfusion of blood substitutes once a week, administering generally fortifying drugs, treating affected area by ultrasound, carrying out antibacterial therapy according to sensitivity of secondary microflora in focus with paracentetically administering angioprotectors into exterior femoral artery on affected side once a day (from 7 to 14 infusions). These steps allow obtaining high concentrations of chemopreparations in locus vascularization zone. Five patients suffering from pedal mycetoma from one to twenty years were treated by disclosed method. EFFECT: shorter treatment and pre-operation periods, lower rate of relapses, longer remission period, rapid stabilization of destructive changes, suppressed adverse toxic effect of chemopreparations on patient's organism by curtailing daily dosage and creating favorable conditions for concentration of chemopreparations in affection focus, and prompt cupping of algesic syndrome and lymphostasis. 1 tbl
Subjects in the EX group will perform supervised exercise 5 d/wk. Exercise will consist primarily of walking on an inclined motor-driven treadmill, but alternate activities will be permitted for 20% of the total exercise sessions (1 of 5 days). Exercise sessions will be preceded by a 5 min warm-up performed at a HR corresponding to 40% of VO2max. The initial exercise duration and intensity at baseline will be 20 minutes at an intensity that elicits a heart rate (HR) corresponding to 60% of VO2max. The target EE will be achieved by a gradual progression of exercise duration and intensity over the first 8 weeks of the exercise program. The target exercise intensity will be the workload corresponding to 75% of VO2max.
PCT No. PCT/FR90/00684 Sec. 371 Date Mar. 10, 1992 Sec. 102(e) Date Mar. 10, 1992 PCT Filed Sep. 25, 1990 PCT Pub. No. W091/04679 PCT Pub. Date Apr. 18, 1991.Method and apparatus for the continuous treatment of reduced thickness article surfaces, for example, for the surface treatment of fragile products of small dimensions. The product to be treated is continuously poured, along with a treatment product, if necessary, into a rotary cylinder arranged horizontally or substantially horizontally, and rotated at low speed. A helical brush is also rotated at a reduced speed in an opposite direction to the cylinder, with the brush being arranged parallel to the cylinder and in contact on at least one of its generating lines with at least one internal generating line of the lower portion of the cylinder.
Cystic fibrosis (CF) is a rare disease with congenital deterioration in mucociliary clearance that causes recurrent or chronic rhinosinusitis, airway infection and bronchiectasis in pediatric age. There are pulmonary genetic disorders associated with inflammation. Children with CF have been shown to have vascular endothelial dysfunction compared to healthy children. Very young children with CF have been reported to have increased arterial stiffness and some decrease in right-left ventricular function. In another study on the subject, it was found that stiffness of the great arteries increased in children with CF; The change in arterial compliancy has been shown to be significant in childhood. The increase in arterial stiffness is associated with systemic inflammation, regardless of blood pressure or diabetes. Hemodynamic changes have been reported in the presence of systemic inflammation in children with CF. Exercise peak workload in children with CF is known to be associated with endothelial dysfunction. It is not known how exercise capacity is affected by endothelial dysfunction and arterial stiffness in CF patients of varying severity. In the literature, there are no studies comparing endothelial function, arterial stiffness and its effect on exercise capacity and pulmonary functions in CF children; this subject is open to research. The aim of this study was to investigate and compare microvascular (peripheral endothelial), macrovascular (arterial stiffness) functions in children with CF and to investigate the relationship of micro and macrovascular functions with exercise capacity and pulmonary functions in children with CF of different obstruction severities.
PURPOSE: An avian infectious bronchitis virus and a vaccine containing the same for avian infectious bronchitis are provided to effectively block the virus. CONSTITUTION: An avian infectious bronchitis virus AVN2/08 strain is deposit number KCTC 11468BP. A vaccine for preventing avian infectious bronchitis contains the avian infectious bronchitis virus AVN2/08 strain. The vaccine is used in preventing avian infectious bronchitis. The vaccine is subunit vaccine, vector vaccine, chimera vaccine, or DNA vaccine using a gene of the virus strain. The vaccine contains veterinarily acceptable intermediate or excipient and adjuvant.
This invention proposes an agent to block the "fuel supply" that energizes cancer cell growth by protecting surrounding cells to the cancer, particularly stromal fibroblast cells. The invention disables the products of surrounding cells useable for energy conversion by the cancer cell thereby crippling the cell and disabling its growth process. This application describes the use of a formulation of liposomally encapsulated glutathione that is preferably used orally to increase the level of glutathione in tissues in order to prevent and reverse the metabolic changes in cells that results in the formation of the metabolic fuel that supports cancer cells and to prevent the oxidative stress that damages normal support cells such as fibroblasts and can prevent and reverse these cells from the steps of autophagy and mitophagy that results in the cells decreasing the normal mitochondrial production of ATP for energy and resorting to the use of aerobic glycolysis for energy production. The use of oral liposomally encapsulated glutathione will maintain the presence and normal function of caveolin in fibroblast and other cells, thus preventing their conversion to autophagic tumor stromal cells. By stopping the formation of autophagic cells, the production of the metabolic fuel needed by cancer cells is stopped, which results in the death of the cancer cells. Compositions using liposomally encapsulated glutathione and other compounds that enhance the favorable effects of liposomal glutathione on cancer disease are referenced.